Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (ASCT) worldwide. The safety and efficacy of reducing hospital stay for MM patients undergoing ASCT have been widely explored, and different outpatient models have been proposed. However, there is no agreement on the criteria for selecting patients eligible for this strategy as well as the standards for their clinical management. On the basis of this rationale, the Italian Group for Stem Cell Transplantation (GITMO) endorsed a project to develop guidelines for the management of outpatient ASCT in MM, using evidence-based knowledge and consensus-formation techniques. An expert panel convened to discuss the currently available data on the practice of outpatient ASCT management and formulated recommendations according to the supporting evidence. Evidence gaps were filled with consensus-based statements. Three main topics were addressed: (1) the identification of criteria for selecting MM patients eligible for outpatient ASCT management; (2) the definition of standard procedures for performing outpatient ASCT (model, supportive care and monitoring during the aplastic phase); (3) the definition of the standard criteria and procedures for re-hospitalization during the aplastic phase at home. Herein, we report the summary and the results of the discussion and the consensus. 
INTRODUCTION
Multiple myeloma (MM) remains the leading indication for highdose chemotherapy and autologous stem cell transplantation (ASCT) worldwide 1, 2 and the International Guidelines recommend that ASCT should be offered at some point during the treatment program for a medically fit patient. 3, 4 High-dose melphalan (HDM) at 200 mg/m 2 is the standard conditioning for ASCT 5, 6 and, today, the treatment should be considered a safe procedure with a very low transplant-related mortality (TRM). [7] [8] [9] The significant increase in the waiting lists generated concerns about the appropriate use of health care resources and, over the past years, some studies have investigated the safety, efficacy and potential cost advantages of reducing hospital stay for patients undergoing ASCT. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The ease of administering HDM, the relatively low extra-hematological toxicity and the short period of neutropenia 5, 6 make MM patients ideal candidates for outpatient ASCT programs. Standardization of criteria for the outpatient ASCT policy is a relevant goal of the Italian hematology and transplant community and may facilitate comparison of retrospective and prospective data. The Italian Group for Stem Cell Transplantation (GITMO) endorsed a panel of 10 experts in the transplant field (MMa, RML, CG, LC, BB, MO, IL, MMo, GM and AO) to propose a consensus for the selection criteria and management of MM patients for ASCT procedure in the outpatient setting.
METHODS
A working group of 10 experts from 7 GITMO centers, with specific expertise in the field of ASCT, convened four times to:
(a) identify common criteria for selecting MM patients eligible for outpatient ASCT; (b) define standard procedures for the ASCT outpatient including the ASCT outpatient model, supportive care and monitoring during the aplastic phase; (c) define standard criteria and procedures for rehospitalization.
The panel first met on February 2013 and agreed to adopt a nominal group technique to address the above-reported issues. Before each meeting, the moderator (AO) asked experts to propose statements for each relevant item. The statements were posted by e-mail and discussed in a round-robin fashion during the meetings. The discussion was facilitated by a moderator who invited each expert to express his or her opinion. Voting could be requested when the panel did not reach a consensus. The majority rule was adopted in the case of discordance.
An expert methodologist (LP) and an experienced researcher in the field of MM (FC) supported the research and the final version of the consensus. An expert in the management of infections in neutropenic patients (CG) was also involved. 1 Systematic review of the literature An independent librarian carried out a sensitive search in different electronic databases (MedLine, the Cochrane Library (CENTRAL)) to select original research articles on modalities and clinical outcomes of outpatient ASCT in MM. A comprehensive list of terms was tested across databases. Related articles were explored, and a manual search was also performed from retrieved studies. The panel experts were asked to report any article possibly missed. Trial registries (for example, clinicaltrials.gov) were searched for non-published studies in progress. Two investigators read all abstracts. Selected articles had to fulfill the following inclusion criteria: (1) clinical observational or experimental study design, (2) inclusion of at least two patients with ASCT. A full paper was obtained from all the eligible studies and evidence tables were generated.
Quality assessment Randomized controlled trials were evaluated through the validated quality scale suggested by Jadad et al. 28 The expert panel agreed to focus on the main issues linked to background questions and main operative questions (Table 1) . After a detailed evaluation of the main trials in this field (Tables 2 and 3) , 42 specific questions to be addressed separately by each member of the panel were identified (see Supplementary File). For each question, a minimum agreement of 80% was required, and disagreements were resolved by discussion. The panel formulated the final statements and the key recommendations in a plenary GITMO session (September 2014) ( Table 4 ). The final manuscript was updated, reviewed and approved by the panel in July 2015.
BACKGROUND QUESTIONS
What is the standard conditioning for MM patients o 66-year-old candidates for outpatient ASCT? The expert panel agreed to focus on MM patients younger than 66 years, mainly because this homogeneous setting makes acceptable the outpatient ASCT management in the context of a standard conditioning regimen including HDM at 200 mg/m 2 (Table 1) . For patients older than 66 years there is no full agreement on the intensity of HDM, ranging from 100 to 140 mg/m 2 . [29] [30] [31] [32] [33] [34] [35] As recently reviewed, the standard conditioning for younger patients is still HDM at 200 mg/m 2 , and there is not any evidence that the addition of other agents may improve clinical outcomes. 5, 6 Elderly patients may not be good candidates for outpatient ASCT due to their reduced medical fitness and presence of comorbidities. 10 Is the ASCT outpatient model safe as the conventional inpatient ASCT model in MM patients? Reported early morbidity and early mortality rates (TRM at day +100) after conventional inpatient ASCT in younger patients were evaluated. Hematological and extra-hematological toxicities and TRM were compared with those reported in studies on outpatient ASCT models in MM.
MM patients who received myeloablative regimens followed by ASCT developed severe hematological toxicity and duration of aplasia was strictly associated with the amount of CD34+ cells infused. A dose ⩾ 2 × 10 6 CD34+ cells/kg body weight is characterized by a rapid neutrophil (PMN) recovery in most patients. 36 No significant advantage has been reported with a CD34+ cell dose higher than 2 × 10 6 CD34+ cells/kg regarding PMN recovery while a significantly slower platelet recovery has been observed when compared with doses higher than 5 × 10 6 CD34+ cells/kg. [36] [37] [38] [39] [40] [41] According to the current literature, [42] [43] [44] expert panel agreed to define a graft content of ⩾ 2 × 10 6 CD34+ cells/kg as the standard minimal dose. Moreover, a higher number of CD34+ cells (for example, 3-5 × 10 6 /kg) was considered the ideal to minimize the risk of delayed engraftment.
The following end points for hematological toxicity were selected: (1) days of severe neutropenia; (2) requirement of transfusion support; (3) days to PMN and platelet engraftment defined as the second consecutive day with PMN 4500/mmc and platelet 420 000/mmc, without transfusion support for ⩾ 3 days.
As for extra-hematological toxicity, the following end points were selected: (1) incidence of neutropenic fever 438°C (NF); (2) days of NF; (3) days of IV antibiotics; (4) incidence of documented severe infections; (5) incidence of severe (grade 3-4 according to WHO definitions) mucositis; (6) incidence of major bleedings.
The expert panel agreed that, besides NF, mucositis represents the most frequent complication, although its incidence after HDM was extensively reported in a few reports. 20, 22, 26 Recent meta-analyses evaluated early TRM in the main randomized studies in MM, which compared ASCT with chemotherapy, and single versus tandem ASCT. TRM was 3%, slightly higher after the second ASCT. [45] [46] [47] In a recent large prospective trial, a TRM between 1 and 3% was reported. 48 In a US study, early TRM was 2% in the 1995-1999 cohort, 2% in the 2000-2004 cohort and 1% in the 2005-2010 cohort. 9 Our recent national survey in 522 procedures, performed on an outpatient basis, showed an early TRM of 1%. 26 Similar data were reported by Gertz et al. 20 and Helbro et al.
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Which is the preferred model for ASCT outpatient management in MM patients?
The most representative models of ASCT as an outpatient procedure are summarized in Figures 1 and 2 . There are only a few data to estimate the real impact of outpatient ASCT Tables 2 and 3 .
The panel agreed that differences in ASCT outpatient models and their clinical outcomes in MM might heavily rely on local conditions. However, the panel agreed to recommend the most frequently implemented model reported in the GITMO survey, which is the 'early-discharge outpatient model' (EDOM) that allowed a very low re-admission rate 26 ( Figure 1 ). Two additional issues that influence outpatient ASCT models are the costeffectiveness and quality of life. Various issues must be considered in economics studies, including medical and non-medical direct costs, indirect costs, pre-transplant and post-transplant costs.
A randomized study compared outpatient ASCT with standard inpatient ASCT in 131 patients with non-leukemic malignant diseases and showed that the early-discharge model allowed discharge on day 0, home stay with a caregiver and outpatient follow-up with, however, a re-admission rate of 86%. 21 In this study, HDM was used as conditioning in only 30% of the patients, and the study population was extremely heterogeneous.
The panel agreed that a cost analysis in this setting required prospective studies. Last, there are not prospective studies comparing the quality of life (QOL) in MM patients treated with outpatient ASCT models. Therefore, the panel agreed that strong recommendations in this setting cannot be established.
OPERATIVE QUESTIONS
How to select MM patients for outpatient ASCT General recommendations. The expert panel agreed that some specific conditions led to define different inclusion/exclusion criteria from those currently accepted for conventional inpatient ASCT. Moreover, very few data on the outpatient ASCT management of MM patients with impaired renal function or other comorbidities are reported. 49, 50 The expert panel selected a list of major criteria to enroll patients in an outpatient ASCT program. A set of specific questions was answered by each panel members and the results with the final list of inclusion/exclusion criteria are reported in the Supplementary File. The panel agreed that advanced age (⩾65 years), poor performance status or presence of relevant Abbreviations: ASCT = autologous stem cell transplantation; EDM = early discharge model (see Figure 1 for details); HDM = high-dose melphalan; HPC = hemopoietic progenitor cell; MIOM = mixed impatient-outpatient model (see Figure 1 for details); MM = multiple myeloma; PCP = primary care provider; TIA = transit ischemic attack; TOM = total outpatient model (see Figure 1 for details).
Outpatient transplantation in multiple myeloma M Martino et al comorbidities were exclusion criteria. 29 The risk of infections should also be carefully evaluated. Local epidemiology, infectious history and colonization status by MDR pathogens require a proper risk assessment for post-transplant infections.
Pre-transplant infections. A history of any severe infection before transplant and the persistence of any microbiological or clinical findings that indicate an incomplete resolution of an infection should be considered a contraindication to outpatient ASCT. Though completely resolved, a history of severe infections by Gram-negative MDR pathogens during the prior 3 months is a contraindication to outpatient ASCT.
Pre-transplant infectious screening. Chest X-ray (or CT scan in selected cases) and additional tests, as clinically indicated, should be performed before transplant. In patients without documented colonization by Gram-negative MDR pathogens, a rectal swab culture should be performed before transplant. When EDOM is planned, colonization monitoring should be started before discharge if a Gram-negative MDR pathogen infection (or colonization) is documented on the hospital ward. Colonization screening should focus on the search of extended spectrum beta-lactamases producer and carbapenemresistant enterobacteria, and of other Gram-negative MDR pathogens (that is, Pseudomonas aeruginosa, Acinetobacter spp, Stenotrophomonas maltophilia). Colonization by carbapenemresistant and Gram-negative MDR pathogens is a contraindication to outpatient ASCT given the crucial role played by timely MDRtargeted empiric antibiotic therapy in carriers of MDR bacterial infections. 51, 52 Colonization by extended spectrum betalactamases producing Enterobacteriaceae do not represent an absolute contraindication, but should be taken into account if empiric antibacterial therapy is required during NF (see below).
Inclusion criteria. The expert panel recommended the following inclusion criteria: (1) age between 18 and 65 years; (2) normal cardiac and lung function as usually performed before a conventional ASCT; (3) absence of other relevant organ dysfunctions. Liver impairment, defined as total bilirubin 43 mg/dL, or renal impairment, defined as a creatinine clearance o60 ml/min; (4) absence of advanced disease (for example, o PR); (5) absence of Gram-negative MDR pathogens colonization or infection during the prior 3 months from ASCT. Any severe infection not completely microbiologically or clinically resolved is considered a contraindication to outpatient ASCT; (6) place of stay within 1 h drive from the hospital; (7) availability of a suitable caregiver 24 h/ 24 h; (7) a dedicated phone line 24 h/24 h at each transplant center to allow patients or their caregivers to contact an expert physician on the transplant team; (8) informed consent including a detailed SOP for the caregiver and the outpatient management. Abbreviations: ASCT = autologous stem cell transplantation; EDM = early discharge model (see Figure 1 for details); EDOM = early-discharge outpatient model; HC = home care (see Figure 1 for details); HDM = high-dose melphalan; IN = inpatient; MM = multiple myeloma; PEG = PEGylated G-CSF; TOM = total outpatient model (see Figure 1 for details).
Outpatient transplantation in multiple myeloma M Martino et al
Which supportive therapy for outpatient ASCT? Supportive care. Supportive care should not differ from that recommended for conventional ASCT. It should include hydration, management of emesis and metabolic disorders, analgesic therapy and transfusion of blood products. All these treatments can routinely be performed in outpatient rooms except for severe medical conditions requiring hospitalization (see below). Patients with severe mucositis (4grade 2 WHO), unable to drink and The main causes are neutropenic fever and mucositis, panic or insecurity The septic shock or multiorgan failure are very rare events in this setting
In the case of fever, without hemodynamic instability or other relevant symptoms, Amoxicillin/Clavulanate (1 g every 12 h orally) should be added to the current prophylaxis with quinolones. In the presence of moderate mucositis (nausea, vomiting, mild dysphagia, diarrhea), Fluconazole at 200-400 mg/day may be added. In case of fever associated with respiratory distress, oliguria or hemodynamic instability, the patients should be quickly re-hospitalized Abbreviations: ASCT = autologous stem cell transplantation; CVC = central venous catheter; F-U = follow-up; HDM = high-dose melphalan; MM = multiple myeloma; PICC = peripherally inserted central catheter; PS = performance status. a Jagannath et al.
14 and Martino et al.
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Inpatient clinic Outpatient clinic CVC Insertion
HDC administration HPC infusion
Hospital stay of approximately 3-4 days Supportive care managment for the aplastic phase Figure 1 . Autologous stem cell transplantation for multiple myeloma through an early-discharge outpatient model. In-hospital admission for conditioning and HPC infusion with discharge on day one post-infusion. Homestay during the aplastic phase with a caregiver (about 10 days) during which twice a week ambulatory visits are scheduled to deliver supportive care if required. HPC = hemopoietic progenitor cell.
Outpatient transplantation in multiple myeloma M Martino et al requiring continuous treatment with major analgesic drugs should rapidly be re-admitted. The expert panel agreed that supportive therapies may vary in the light of the different outpatient ASCT models. Two outpatient ASCT models are employed in the GITMO network: the EDOM and delayed admission model (DAM). 53 In the EDOM model, 10,23,26 the most commonly used in Italy, patients and caregivers should carefully trained on home behavior and a detailed information sheet on the management of mild/moderate mucositis, fever or mucosal bleeding should be provided for the general practitioner. In the delayed admission model, discharge is scheduled on day 1 and re-admission on day 5 post-HSC infusion. The results of this approach, however, do not strongly support that the delayed admission model may significantly reduce hospital stay and its costs when compared with the other model. Antimicrobial prophylaxis. The expert panel agreed that antimicrobial prophylaxis for outpatient ASCT should not differ from that recommended for conventional inpatient ASCT. [54] [55] [56] [57] [58] Patients should receive antibacterial prophylaxis with ciprofloxacin 500 mg twice daily or levofloxacin 500 mg once a day from day 0 until stable neutrophil engraftment. A recent study suggests that Levofloxacin prophylaxis is associated with decreased risk of bloodstream infection and fever in patients with myeloma undergoing ASCT. 59 Primary antifungal prophylaxis is not recommended in the ASCT setting. 60, 61 However, in the case of symptomatic mucositis, oral fluconazole at 200-400 mg/day should be started until complete hematological recovery. Even though the full resolution may have occurred, secondary antifungal prophylaxis in patients with previous invasive fungal infections is recommended. Antiviral prophylaxis from the day − 2 until neutrophil engraftment for up to 3 months post transplantation or longer at the discretion of the attending physician is recommended. Pneumocystis jiroveci prophylaxis is recommended after engraftment and for 3 months post transplant or until a satisfactory immunological recovery (CD4+ lymphocytes cells 4200/mmc).
Infection monitoring. After discharge, the first follow-up visit should be recommended at day +5 and then scheduled twice weekly until sustained hematological recovery. Patients and caregivers and family members should be properly trained on careful monitoring of fever and other infectious signs/symptoms. Surveillance blood cultures in the absence of fever or other infection signs are not required regardless of the presence of a central venous catheter. Finally, surveillance for fungal infections with biomarkers (that is, plasma galactomannan, beta-D-glucan, fungal PCR) is not required.
Management of neutropenic fever. In the event of fever (body temperature 438°C in two measurements or 438.3°C as a single measurement) during neutropenia, patients should be evaluated within 1-2 h by an expert hematologist on call who will decide on the need for hospitalization and the choice of the antimicrobial therapy. The expert panel strongly suggests a 24-h active phone line with the hematologist on call in the BMT unit. According to the local policy and based on clinical conditions, the clinical examination may be performed either at home, by the general practitioner or in an emergency department, in case of worrying symptoms and/or a low MASC score; in both cases, the general practitioner will be able to give an immediate feedback to the hematologist on call and (if needed) to start an oral antibiotic treatment. The expert panel recommends that a detailed standard operative procedure in the case of NF should be available contextually at the time of the informed consensus (a dedicated form must be prepared for the outpatient ASCT procedure), not only for the patient but also for the caregiver and the general practitioner. The evaluation of the febrile episode should include a physical exam, at least, two blood cultures and imaging when clinically indicated.
Which re-admission criteria and how to manage ASCT outpatients with significant complications? Re-admission criteria should include: (a) severe mucositis (with/without fever) unresponsive to outpatient management; (b) fever with grade ⩾ 2 mucositis; (c) fever 438.3°C should be evaluated within 1-2 h from onset by an expert hematologist (at least by phone, see paragraph 'Management of NF'). Overall, in patients with a-b-c blood pressure, O 2 saturation and vital signs should carefully be monitored. After at least 6 h monitoring, hemodynamically stable patients without relevant clinical problems may be followed as outpatients. The expert panel agreed on the potential usefulness of the MASCC score, 62 although this index has not been validated in the ASCT setting. An MASCC score as low as 21 or lower (high-risk patients) was considered a criterion for rapid re-admission through a score higher than 21 was not considered a sufficient criteria per se to define patient at low risk and delay re-admission. In case of NF the panel agreed on the following re-admission criteria:
• Hemodynamic instability (for example, tachycardia and low blood pressure), impaired respiratory function (increased respiratory frequency and low oximetry on room air), oliguria, altered mental status and other signs of clinical instability.
• Grade 42 oral mucositis and diarrhea.
• Colonization by extended spectrum beta-lactamases producing Enterobacteriaceae (colonization by other MDR pathogens).
• Fever persisting after 2 days of broad spectrum antibacterial therapy.
• Low compliance of the patient.
The use of empiric antibacterial therapy should follow guidelines/recommendations for patients with hematologic malignancies and NF. Empiric broad-spectrum antibacterial therapy should be initiated within 1 h from clinical evaluation and after blood cultures have been obtained, and fever workup has been completed. IV antibiotics should be preferred and chosen in the light of clinical and laboratory findings. Outpatient oral antibiotic therapy (that is, amoxicillin-clavulanate) in low-risk patients may be considered.
How to optimize the performance of ASCT outpatients? The expert panel also addressed three potentially relevant issues which may be critical to improving the performance of the outpatients ASCT model:
• Re-hospitalization;
• NF incidence; • QOL.
Re-hospitalization for outpatients is most commonly due to severe oral mucositis (grade 3-4 WHO) which requires TPN and narcotic analgesics; NF unresponsive to oral antibiotics which impairs PS or determines hemodynamic instability; psychological distress or loss of caregiver support.
Decreased incidence of mucositis in patients transplanted as outpatients is of pivotal importance given that mucosal damage increases the risk of many complications that may easily cause readmission. Palifermin administered pre-and post-HDM was studied in a randomized fashion with no beneficial effect on mucositis incidence and on fever. 63 Other studies, however, found a positive impact of palifermin on infection rate after BEAM-like conditionings or after TBI. [64] [65] [66] Furthermore, some studies suggested that, though palifermin was not effective in reducing overall infection rate (mostly central venous catheter related), its use may reduce 'severe' infections such as those due to Gramnegative pathogens or accompanied by focal pneumonia. 66, 67 In many centers, G-CSF administration is not routinely performed when the source of hematopoietic cells is mobilized peripheral blood, and the dose of CD34+ cells infused is largely above the threshold required for a proper engraftment. When a CD34+ cell dose 45 × 10 6 /kg is employed, neutropenia is unlikely to be further shortened by the administration of post-transplant G-CSF. Filgrastim and lenograstim are the standard G-CSF molecules used for enhancing neutrophil recovery after ASCT. Very few data on the use of biosimilar G-CSFs have been reported so far 68, 69 though they have successfully been used for HSC mobilization. 69 PEGylated G-CSF was also used 70, 71 and, in the GITMO survey, many patients on outpatient ASCT programs were given PEG-G-CSF. 26 The issue about the global economics involved in the outpatient ASCT procedure is still debated. However, several experiences suggest that this approach could induce a significant sparing of the direct costs, due to the reduced number of hospitalization in intensive care unit. 23, 24 CONCLUSIONS Notwithstanding its appeal, outpatient ASCT in MM has not yet been established as a routine procedure, and many transplant centers are reluctant to adopt this approach. However, the extensive use of some outpatient ASCT models in MM may contribute to making ASCT more competitive especially when compared with some expensive new drugs. Among the different approaches, the mixed inpatient/outpatient model was shown to be highly feasible with a very low re-hospitalization rate and without increased TRM. One of the reasons for its low implementation may be the lack of specific reference recommendations/guidelines. The present consensus may represent a valid tool to widen this policy to both Italian and European transplant centers.
